SCHEMBL4433185

SCHEMBL4433185

O=C(O)Cc1cccc(Oc2cccc(-c3ccc(Cl)cc3)c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 5/20 0.51
FFAR1 O14842 3/20 0.50
FFAR4 Q5NUL3 3/20 0.50
PPARG P37231 1/20 0.50
PPARA Q07869 1/20 0.50
SHMT1 P34896 1/20 0.50
SHMT2 P34897 1/20 0.50
THRA P10827 3/20 0.48
THRB P10828 3/20 0.48
DAGLA Q9Y4D2 1/20 0.48
ABCC4 O15439 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.46
PTGS1 P23219 1/20 0.46
HTT P42858 1/20 0.46
P2RX3 P56373 1/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4440017 0.90 PTGDR2 (0.52) PTGDR2FFAR1FFAR4PPARGPPARA
SCHEMBL1421946 0.88 PPARG (0.61) PTGDR2FFAR1FFAR4PPARGPPARA
SCHEMBL4904635 0.88 KMO (0.49) PTGDR2FFAR1FFAR4THRATHRB
SCHEMBL4440031 0.87 FFAR1 (0.55) FFAR1FFAR4THRATHRBLMNA
SCHEMBL4434293 0.87 THRA (0.46) PTGDR2FFAR1FFAR4THRATHRB
SCHEMBL4213065 0.87 SHMT1 (0.62) PTGDR2SHMT1SHMT2ABCC4LMNA
SCHEMBL4441221 0.86 MRGPRX4 (0.56) PTGDR2FFAR1FFAR4THRATHRB
SCHEMBL5126060 0.85 RXRA (0.52) FFAR1FFAR4PPARGTHRATHRB
SCHEMBL4433180 0.85 FFAR1 (0.60) PTGDR2FFAR1FFAR4THRATHRB
SCHEMBL4431271 0.85 FFAR1 (0.48) PTGDR2FFAR1FFAR4THRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121591-A2 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2009-11-25 EP disclosed
WO-2008109697-A2 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2008-09-12 WO disclosed
US-20080221127-A1 peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance PLEXXIKON INC 2008-09-11 US disclosed
US-20080221127-A1 peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance PLEXXIKON INC 2008-09-11 US disclosed
US-20080221127-A1 peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance PLEXXIKON INC 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221127-A1 peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance PPARA, PPARG, PPARD PTGDR2 626/4885FFAR1 30/4885FFAR4 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.